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545Abstracts
of expertise have organized, collaborative links with 
community home care services and sufﬁcient resources.
CONCLUSIONS: Home chemotherapy requires a well-
integrated multidisciplinary team of health professionals
in partnership with selected patients and their informal
caregivers. Our study shows the need for regionalized
approaches within centralized standard setting and
funding, increased resources and support for program
evaluation, and a comprehensive cancer care model.
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OBJECTIVES: Poor glycaemic control is associated with
increased risk of micro- and macro-vascular disease in
type 2 diabetes (T2D) patients. Switching patients from
metformin to Glucovance (combined glibenclamide/
metformin) leads to improved glycaemic control in pre-
viously poorly controlled patients. No long-term studies
have been performed that compare complication rates,
mortality, and long-term costs in patients switched from
metformin to Glucovance. A method was sought to link
the effects on glycaemic control of switching from met-
formin to Glucovance to long-term complication rates
and associated costs. METHODS: A validated model was
used to quantify the improvements in life expectancy
(LE), the changes in total lifetime costs (TC) associated
with the improved glycaemic control seen with switching
patients from metformin to Glucovance. Standard
Markov modelling was used to describe the long-term
incidence and progression of diabetes-related complica-
tions (angina, MI, stroke, heart failure, peripheral vascu-
lar disease, neuropathy, foot ulcer, amputation, renal
disease, and eye disease). Probabilities of complications
and HbA1c-dependent adjustments were derived from
published studies. Switching from metformin to Glucov-
ance lead to a 1% point improvement in HbA1c. Direct
costs of diabetes complications and treatment with either
metformin or Glucovance were projected over patients’
lifetimes (discounted 5% p.a.). Costs of complications
were retrieved from published sources. A French third
party payer perspective was taken. A typical type 2 
diabetes cohort (baseline age of 59) was simulated over a
30 years period. Exstensive sensitivity analysis was 
performed. RESULTS: Improved glycaemic control 
after switching from metformin to Glucovance lead to
decreased incidence and progression of diabetes-related
complications, with an increase in LE of 0.80 years, and
reduction in TC/patient of €2,050. CONCLUSIONS:
Switching from metformin to Glucovance is dominant to
maintaining patients on MET monotherapy with poor
control. Further long-term clinical studies with economic
data collection are required to conﬁrm these results.
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OBJECTIVES: To estimate the cost-effectiveness of
glycemic control with pioglitazone hydrochloride com-
pared to conventional treatment for Japanese patients
with Type II diabetes. METHODS: This study used the
Japanese Diabetes Risk Simulation Software to estimate
the lifetime cost per life-year or quality-adjusted life year
(QALY). The hypothetical cohort was comprised of 1000
individuals living in Japan, aged 50 years, who were
newly diagnosed as having Type II diabetes without
retinopathy, nephropathy complications or history of
coronary heart disease (CHD). Clinical effectiveness data
were taken from the results of clinical trials conducted in
Japan. Cost data were based on the fee schedule used for
hospital outpatients in 2000. Costs (in 2000, Japanese
yen), life expectancy and QALYs were discounted at 3%
per annum. RESULTS: Glycemic control with pioglita-
zone hydrochloride reduced the cumulative incidence of
blindness, dialysis and CHD by 22.2%, 12.2% and
7.9%, respectively. As a result, it produced a net saving
of 390,000 yen per patient over the lifetime despite the
additional annual cost of 70,000 yen for pharmacother-
apy. Increased life expectancy was 0.61 years, and 0.68
QALYs was gained. CONCLUSIONS: Glycemic control
with pioglitazone hydrochloride reduces costs and
improves health outcomes relative to conventional treat-
ment in patients with Type II diabetes in Japanese clini-
cal settings.
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OBJECTIVES: In the Diabetes Prevention Program
(DPP), overweight patients with impaired glucose toler-
ance randomized to either intensive lifestyle changes
(ILC) or metformin (MET) reduced their risk of develop-
